A Phase 1 interventional study of dabigatran etexilate and rivaroxaban in Thrombosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-02.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 30 studies testing rivaroxaban in Thrombosis — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thrombosis.
Among the 30 studies testing rivaroxaban in Thrombosis, this one is the 22nd largest by enrollment, is the only one that started in 2011, is one of 7 in phase 1, and was the 5th registered.
955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.
Browse Thrombosis studies →4 of the 30 studies testing rivaroxaban in Thrombosis are open now, in 4 countries. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Queen Mary University of London · Sites in United Kingdom
Ages 16+
Nova Scotia Health Authority · Sites in Canada
Ages 55+
Lebanese University · Sites in Lebanon
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
30 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 11 · Phase 4 5
First in 2004; this study’s year is marked. 1 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 83 across 530 interventional studies indexed under Thrombosis.
Median enrollment 84 across the 30 interventional studies. Of the 22 that completed or were terminated, 11 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 30 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Merck & Co., Inc has 2 studies filed under Thrombosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing rivaroxaban in Thrombosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613840Massachusetts General HospitalPersonalizing Thromboprophylaxis for Patients With Peripheral Artery Disease | 2027-04-29 |
Add it to your calendar (.ics) → With an account.
Among the 30 studies testing rivaroxaban in Thrombosis, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Inclusion criteria for non-hemophilia participants:
Panel A
Panel B
Both Panels
Exclusion criteria for non-hemophilia participants:
Inclusion criteria for hemophilia participants:
Exclusion criteria for hemophilia participants:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single 150-mg dose of dabigatran etexilate
Drug: dabigatran etexilate
Single 20-mg dose of rivaroxaban
Drug: rivaroxaban
No study drug will be administered
dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
Endogenous thrombin potential by Thrombin Generation Assay (TGA)-2a assay
Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose
Level of fibrin degradation product (D-dimer)
Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose
Level of fibrinopeptide A (FPA)
Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose
Level of prothrombin split products (F1+2)
Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose
Level of thrombin-antithrombin complex (TAT)
Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose
No study locations are listed for this record.
The record gives a start of May 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dabigatran · Rivaroxaban